Comparative study on the immunogenicity and safety of a purified chick embryo cell rabies vaccine (Pcecv) administered according to two different simulated post exposure intramuscular regimens (zagreb versus essen)

Human Vaccines and Immunotherapeutics

Volumn 11, Issue 2, 2015, Pages 428-434

  Mahendra, B J ^a   Ashwath Narayana, D H ^b   Agarkhedkar, Sharad ^c   Ravish, H S ^b   Harish, B R ^a   Agarkhedkar, Shalaka ^c   Madhusudana, S N ^d   Belludi, Ashwin ^d   Ahmed, Khaleel ^e   Jonnalagedda, Rekha ^e   Vakil, Hoshang ^f   Bhusal, Chiranjiwi ^g   Arora, Ashwani Kumar ^g  

^a Mandya Rajiv Gandhi University of Medical Sciences   (India)

^b KEMPEGOWDA INSTITUTE OF MEDICAL SCIENCES   (India)

^c HOSPITAL AND RESEARCH CENTRE   (India)

^d NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

^e Novartis Vaccines   (India)

^f Novartis Vaccines   (India)

^g NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

Essen; India; PCECV; Rabies; Zagreb

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN; RABIES VACCINE; VIRUS ANTIBODY;

ACALCULIA; ADULT; AGGRESSION; ALZHEIMER DISEASE; AMNESIA; APRAXIA; ARTICLE; AUTOPSY; CALORIC INTAKE; CASE REPORT; CEREBRAL BLINDNESS; COGNITIVE DEFECT; ENVIRONMENTAL FACTOR; FACIAL EXPRESSION; FEMALE; GAIT; HALLUCINATION; HUMAN; HUMAN TISSUE; MALE; MARRIED PERSON; MIDDLE AGED; MYOCLONUS; PHOTOPHOBIA; VASCULAR AMYLOIDOSIS; ADVERSE EFFECTS; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; INDIA; INTRAMUSCULAR DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; NORMAL HUMAN; POST EXPOSURE PROPHYLAXIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SERODIAGNOSIS; VACCINATION; YOUNG ADULT;

ADULT; ANTIBODIES, VIRAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INDIA; INJECTIONS, INTRAMUSCULAR; MALE; NEUTRALIZATION TESTS; POST-EXPOSURE PROPHYLAXIS; RABIES VACCINES; VACCINATION; YOUNG ADULT;

EID: 84929081908     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/21645515.2014.995059     Document Type: Article

References (25)

1. Nandi S, Kumar M. Development in Immunoprophylaxis against Rabies for Animals and Humans. Avicenna journal of medical biotechnology 2010; 2:3-21; PMID:23407587
2. (WHO) WHO. Rabies Vaccines: WHO position paper. Weekly epidemiological record 2010; 32:309-20; PMID:18064757
3. Menezes R. Rabies in India. CMAJ : Canadian Medical Association journal D journal de l’Association medicale canadienne 2008; 178:564-6; PMID:18299543; http://dx.doi.org/10.1503/cmaj.071488
4. Hemachudha T, Wacharapluesadee S, Mitrabhakdi E, Wilde H, Morimoto K, Lewis RA. Pathophysiology of human paralytic rabies. Journal of neurovirology 2005; 11:93-100; PMID:15804967; http://dx.doi.org/ 10.1080/13550280590900409
5. Gadre G, Satishchandra P, Mahadevan A, Suja MS, Madhusudana SN, Sundaram C, Shankar SK. Rabies viral encephalitis: clinical determinants in diagnosis with special reference to paralytic form. Journal of neurology, neurosurgery, and psychiatry 2010; 81:812-20; PMID:19965838; http://dx.doi.org/10.1136/jnnp. 2009.185504
6. WHO. WHO prequalified vaccines. 2012.
7. Ministry of Health & Family Welfare GoI. National Guidelines for Rabies Prophylaxis and Intra-dermal Administration of Cell Culture Rabies Vaccines. 2007
8. Ichhpujani RL, Chhabra M, Mittal V, Bhattacharya D, Singh J, Lal S. Knowledge, attitude and practices about animal bites and rabies in general community–a multi centric study. The Journal of communicable diseases 2006; 38:355-61; PMID:17913213
9. Baxter JM. One in a million, or one in thousand: What is the morbidity of rabies in India? Journal of global health 2012; 2:010303; PMID:23198128; http://dx. doi.org/10.7189/jogh.01.010303
10. Chutivongse S, Wilde H, Fishbein DB, Baer GM, Hemachudha T. One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 1991; 9:573-6; PMID:1771970; http://dx.doi.org/10.1016/ 0264-410X(91)90244-Z
11. Colnot F, Sureau P, Alexandre JL, Arnaudo JP, Hesse JY, Jeanmaire H. [Post-exposure antirabies vaccination. Early serological response to vaccine cultivated on VERO cells using a reduced 2-1-1 schedule]. Presse Med 1994; 23:1609-12; PMID:7831241
12. Liu H, Huang G, Tang Q, Li J, Cao S, Fu C, Cao Q, Liu B, Pan H, Wang M. The immunogenicity and safety of vaccination with purified Vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen. Human vaccines 2011; 7:220-4; PMID:21311216; http://dx. doi.org/10.4161/hv.7.2.14003
13. WHO. Rabies Vaccines: WHO Position Paper. 2010
14. Sudarshan MK, Narayana DH, Madhusudana SN, Holla R, Ashwin BY, Gangaboraiah B, Ravish HS. Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India. Human vaccines & immunotherapeutics 2012; 8:1077-81; PMID:22699446; http://dx.doi.org/10.4161/hv.20471
15. Zalan E, Wilson C, Pukitis D. A microtest for the quantitation of rabies virus neutralizing antibodies. Journal of biological standardization 1979; 7:213-20; PMID:387798; http://dx.doi.org/10.1016/S0092- 1157(79)80024-4
16. Moore SM, Hanlon CA. Rabies-specific antibodies: measuring surrogates of protection against a fatal disease. PLoS neglected tropical diseases 2010; 4:e595; PMID:20231877; http://dx.doi.org/10.1371/journal. pntd.0000595
17. Wunner WH, Jackson AC. Rabies: Scientific Basis of the Disease and Its Management. Academic Press, 2010
18. Vodopija I, Sureau P, Lafon M, Baklaic Z, Ljubicic M, Svjetlicic M, Smerdel S. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 postexposure schedule. Vaccine 1986; 4:245-8; PMID:3541428; http://dx.doi.org/10.1016/0264- 410X(86)90138-6
19. (WHO) WHO. WHO Expert Committee on Rabies. WHO Technical Report 1992: 1-84.
20. Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, Lett S, Levis R, Meltzer MI, Schaffner W, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine 2009; 27:7141-8; PMID:19925944; http://dx.doi.org/10.1016/j. vaccine.2009.09.029
21. Vodopija I, Baklaic Z, Vodopija R. Rabipur: a reliable vaccine for rabies protection. Vaccine 1999; 17:1739-41; PMID:10194832; http://dx.doi.org/10.1016/ S0264-410X(98)00427-7
22. Vodopija I, Sureau P, Smerdel S, Lafon M, Baklaic Z, Ljubicic M, Svjetlicic M. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. Vaccine 1988; 6:283-6; PMID:3420976; http://dx.doi. org/10.1016/0264-410X(88)90225-3
23. Lang J, Simanjuntak GH, Soerjosembodo S, Koesharyono C. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of postexposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. Bulletin of the World Health Organization 1998; 76:491-5; PMID:9868840
24. Huang G, Liu H, Tang Q, Yu P, Shen X, Zhang Y, Liu X, Cao Q, Fu C, Liu B, et al. Making rabies prophylaxis more economical: Immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers. Human vaccines & immunotherapeutics 2013; 10:1, 114-19; PMID:24008819; http://dx.doi.org/10.4161/hv.26264
25. Kulkarni PS, Sapru A, D’Costa PM, Pandit A, Madhusudana SN, Yajaman AB, Mangrule S, Gunale B, Bavdekar AR. Safety and immunogenicity of a new purified vero cell rabies vaccine (PVRV) administered by intramuscular and intradermal routes in healthy volunteers. Vaccine 2013; 31:2719-22; PMID: 23583817; http://dx.doi.org/10.1016/j.vaccine.2013.03.050